Ivabradin Beta

Ivabradine, the active ingredient in Ivabradin Beta, is a If channel inhibitor presented as a tablet for oral use. It is indicated for chronic stable angina and heart failure with reduced ejection fraction in adults. GNH USA supplies Ivabradin Beta as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Ivabradine is used in cardiovascular conditions that benefit from selective heart‑rate reduction.

Chronic stable angina: reduces the frequency of angina attacks and improves exercise tolerance. Heart failure with reduced ejection fraction (NYHA class II‑III): lowers heart rate, enhancing functional capacity and decreasing hospitalisations. Elevated resting heart rate despite beta‑blocker therapy: provides additional rate control without affecting contractility.

Ivabradine may cause a range of adverse reactions, most of which are related to its heart‑rate‑lowering action or visual pathways.

Common Side Effects: - Luminous phenomena (phosphenes) or transient visual disturbances. - Headache. - Dizziness or light‑headedness. - Nausea. - Fatigue.

Serious or Rare Side Effects: - Severe bradycardia requiring medical attention. - Atrial fibrillation or other arrhythmias. - Symptomatic hypotension. - Visual loss or persistent visual impairment. - Allergic reactions such as rash or angioedema. - Hepatic dysfunction indicated by abnormal liver enzymes.

Before initiating therapy, clinicians should evaluate cardiovascular status and consider potential risks.

Cardiovascular assessment: confirm baseline heart rate and rhythm. Heart‑rate monitoring: check regularly, especially after dose adjustments. Avoid in severe hepatic impairment: dose reduction may be required. Caution with concomitant beta‑blockers or other bradycardic agents. Pregnancy and lactation: safety not established; use only if benefits outweigh risks. Store at room temperature: keep in the original packaging, protect from moisture and heat.

Ivabradine can interact with several drug classes, influencing its efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase plasma levels. - Other bradycardic agents (beta‑blockers, digoxin): risk of excessive heart‑rate reduction. - Calcium‑channel blockers affecting AV conduction (verapamil, diltiazem).

Moderate Interactions (Monitor Closely):\n- CYP3A4 inducers (rifampin, carbamazepine): may reduce effectiveness. - Diuretics causing electrolyte imbalance: monitor for arrhythmias. - Antihypertensive agents: observe blood pressure and heart‑rate response.